Infliximab Articles
Intron slump, charges lead to S-P loss
2 February 2004
J&J 4th-qtr EPS up 35%, sales rise 20%
26 January 2004
Stock Commentary - Tokyo
8 December 2003
Tokyo pharma stocks - week to Dec 1
8 December 2003
Added use for S-P's Remicade OKed by EU
3 November 2003
J&J raises forecast on strong 3rd quarter
20 October 2003
NICE plans six new pharma guidelines for NHS in England/Wales
20 October 2003
Tokyo pharma stocks - week to July 28
4 August 2003
Tanabe to track Remicade users
4 August 2003
Generics push S-P profits down 71%
28 July 2003
Acquisition charges hit J&J 2nd-qtr results
21 July 2003
Tokyo pharma stocks - week to July 7
14 July 2003
Stock Commentary - New York
16 June 2003
Tanabe reports modest growth, misses targets
26 May 2003
S-P's Remicade cleared in EU for Crohn's, AS
26 May 2003
S-P's new CEO sets out turnaround plan
19 May 2003
Remicade: rapid benefit in severe sciatica
21 April 2003
Canadian province OKs TNF blockers
7 April 2003
Tanabe's growth tied to drug development
24 March 2003
Abbott starts Humira trials in psoriasis
17 March 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
Remicade backed for new indication in EU
3 March 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Claritin switch hits S-P, sales down 4% in 2002
3 February 2003
Update - Amgen says Enbrel psoriasis trial is positive
27 January 2003
Remicade fast-tracked for new indication in USA
13 January 2003
XOMA/Genentech file Raptiva BLA in USA
6 January 2003
Abbott gets approval for blockbuster candidate Humira in USA
6 January 2003
Celltech acquires Pharmacia's Dipentum
5 August 2002
Mixed Ph III results for Celltech's CDP 571
5 August 2002
Tokyo pharma stocks - week to July 15
22 July 2002
J&J
22 July 2002
Remicade label extended in USA
8 July 2002
New report brings hope for IBD sufferers
8 July 2002
Stock Commentary - Tokyo
10 June 2002
Stock Commentary - New York
3 June 2002
Tokyo pharma stocks - week to May 27
3 June 2002
Tokyo pharma stocks - week to May 13
20 May 2002
IBD market to double by 2011
13 May 2002
UK NICE OKs Remicade for some Crohn's cases
13 May 2002
1st qtr 2002 "a let down for biotech"
6 May 2002
Tokyo pharma stocks - week to April 22
29 April 2002
J&J earnings climb 18.2% in 1st qtr
22 April 2002
Infliximab shows efficacy in spondylitis
15 April 2002
Remicade gains FDA priority for CD
8 April 2002
Tokyo pharma stocks - week to March 25
1 April 2002
UK NICE's proposed guidance timetable
25 March 2002
Enbrel also active in psoriasis, says study
4 March 2002
Enbrel linked to lupus, says Lancet letter
25 February 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Remicade labeling tightened for safety
11 February 2002
J&J posts healthy increase in sales and earnings for 2001
28 January 2002
Tokyo pharma stocks - week to January 21
28 January 2002
Rheumatoid arthritis market forecasts
14 January 2002
Amgen's Kineret cleared in first market
16 November 2001
New safety data on Amgen's Kineret bode well for its use in RA
14 November 2001
Remicade effective in maintenance of Crohn's remission
26 October 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
Remicade increases mortality in CHF trial
23 October 2001
Amevive out in front amongst new biologicals for psoriasis
16 October 2001
Skepticism over French 2002 health care spending budget
25 September 2001
Stock Commentary - Tokyo
6 September 2001
Japan pharma stocks, week to Sept 3rd
5 September 2001
TNF-alpha inhibitor sales forecast to soar
22 August 2001
Amgen boosted by FDA committee recommendation
20 August 2001
FDA advisory panel meetings
16 August 2001
Stock Commentary - Tokyo
1 August 2001
Japan pharma stocks - week to July 30
31 July 2001
Celltech reaches target with arthritis drug
30 July 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
Japan pharma stocks - week to July 23
25 July 2001
Manufacturing woes hit Schering-Plough
18 April 2001
J&J beats forecasts with 14% EPS rise
18 April 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
